A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia

What Was Tested

Researchers studied Leuprolide in the context of hyperparathyroidism in this randomized controlled trial publication.

The researchers investigated the effect of the luteinizing hormone-releasing hormone agonist leuprolide given as an injection every 28 days for 24 weeks in a double-blind, placebo-controlled trial with 50 evaluable patients along an extensive protocol with the main emphasis on objective parameters for outcome assessment.

Why It Was Studied

Several physicians have used luteinizing hormone-releasing hormone agonists for small, selected groups of patients with benign prostatic hyperplasia but their clinical role in this indication is still not well defined.

Who Took Part

According to the abstract, 50 patients were involved.

By PubMed's age tags, the people studied were older adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Leuprolide and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Leuprolide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Leuprolide group a baseline to be compared against.

The timeline in the abstract includes 24 weeks.

What Was Measured

The subject headings attached to it are Leuprolide, Prostate, Prostatic Hyperplasia and Urodynamics.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Leuprolide in 50 patients in people with hyperparathyroidism over 24 weeks.

The publication is from 1993 (The Journal of urology), a journal based in United States.

More context: the Leuprolide compound page, Hyperparathyroidism research.